• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance

    11/6/24 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results.

    As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at investor.mckesson.com/events-and-presentations.

    About McKesson Corporation

    McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241105449989/en/

    Get the next $MCK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    SEC Filings

    See more
    • SEC Form DEFA14A filed by McKesson Corporation

      DEFA14A - MCKESSON CORP (0000927653) (Filer)

      6/20/25 4:26:12 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form DEF 14A filed by McKesson Corporation

      DEF 14A - MCKESSON CORP (0000927653) (Filer)

      6/20/25 4:19:35 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MCKESSON CORP (0000927653) (Filer)

      6/9/25 8:00:02 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care